{Reference Type}: Journal Article
{Title}: DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer.
{Author}: Li Y;Liao L;Kong L;Jiang W;Tang J;Han K;Hou Z;Zhang C;Zhou C;Zhang L;Sui Q;Xiao B;Mei W;Xu Y;Yu J;Hong Z;Pan Z;Ding P;
{Journal}: Clin Transl Oncol
{Volume}: 25
{Issue}: 1
{Year}: Jan 2023
{Factor}: 3.34
{DOI}: 10.1007/s12094-022-02930-8
{Abstract}: <B>BACKGROUND: </B>For clinically low-risk stage III colorectal cancer, the decision on cycles of adjuvant chemotherapy after surgery is disputed. The present study investigates the use of additional biomarkers of ploidy and stroma-ratio(PS) to stratify patients with low-risk stage III colorectal cancer, providing a basis for individualized treatment in the future.<BR><B>METHODS: </B>This study retrospectively enrolled 198 patients with clinical-low-risk stage III colorectal cancer (T1-3N1M0) and analyzed the DNA ploidy and stroma ratio of FFPE tumor tissues. The patients were divided into PS-low-risk group (Diploidy or Low-stroma) and PS-high-risk group (Non-diploid and High-stroma). For survival analyses, Kaplan-Meier and Cox regression models were used.<BR><B>RESULTS: </B>The results showed that the 5-year DFS of the PS-high-risk group was significantly lower than that in the PS-low-risk group (78.6 vs. 91.2%, HR = 2.606 [95% CI: 1.011-6.717], P = 0.039). Besides, in the PS-low-risk group, the 5 year OS (98.2 vs. 86.7%, P = 0.022; HR = 5.762 [95% CI: 1.281-25.920]) and DFS (95.6, vs 79.9%, P = 0.019; HR = 3.7 [95% CI: 1.24-11.04]) of patients received adjuvant chemotherapy for > 3 months were significantly higher than those received adjuvant chemotherapy for < 3 months. We also found that the PS could stratify the prognosis of patients with dMMR tumors. The 5-year OS (96.3 vs 71.4%, P = 0.037) and DFS (92.6 vs 57.1%, P = 0.015) were higher in the PS-low-risk dMMR patients than those in the PS-high-risk dMMR patients.<BR><B>CONCLUSIONS: </B>In this study, we found that PS can predict the prognosis of patients with stage III low-risk CRC. Besides, it may guide the decision on postoperative adjuvant chemotherapy.